微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Temozolomide
Temozolomide

肿瘤

关键词肿瘤 药物 脑癌

词汇介绍

拓展阅读

解析

Temozolomide

释    义   n. 替莫唑胺

例    句   At recurrence temozolomide is effective for anaplastic tumors; well-tolerated and probably equally effective is PCV used as adjuvant therapy. 对于复发的病人,替莫唑胺对间变胶质瘤是有效的。作为辅助治疗,它和PCV方案有同等的效果。

概述

替莫唑胺胶囊,又叫蒂清胶囊、泰道,是一种用于治疗脑癌的美国进口的药物,可以通过增强放化疗作用,让脑癌患者可以更好地对抗癌细胞。主要成份是替莫唑胺,其化学名为:3,4-二氢-3-甲基-4-氧代咪唑[5,1-d]并1,2,3,5-四嗪-8-甲酰胺。由默沙东公司研发生产,是一种硬胶囊剂,内容物为类白色至淡粉色颗粒状粉末。蒂清是目前唯一治疗脑胶质瘤的口服胶囊制剂,针对性强、特异性高,可透过血脑屏障,是治疗脑胶质瘤及转移瘤的特效药。两年多的临床观察及研究工作显示,蒂清治疗脑胶质瘤效果显著,同时具有延长

Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer复制标题

奥拉帕林联合替莫唑胺治疗复发性小细胞肺癌

发表时间:2019-08-15

影响因子:26.4

作者: Anna F. Farago

期刊:Cancer Discov

Among 50 patients with relapsed SCLC, combination OT shows a strong signal of clinical efficacy. Although cross-study comparisons are difficult to interpret, the confirmed ORR of 41.7% and mPFS of 4.2 months are numerically superior to several recent second- and third-line SCLC studies. The addition of veliparib to temozolomide also showed improved responses in a placebo-controlled randomized phase 2 study, further supporting this strategy. In contrast, monotherapy with the PARP inhibitor talazoparib led to only 2 partial responses among 23 SCLC patients treated in a phase 1 expansion study, and monotherapy olaparib did not confer a PFS benefit compared to placebo when used as a single agent in the maintenance setting after first-line platinum/etoposide. The superiority of the combination over monotherapy was also evident in our PDX models, where OT was significantly more active than either drug alone (Supplementary Figure 2C). Collectively, these data support the further development of strategies that combine induction of DNA damage with PARP inhibition. Such an approach in the SCLC second-line setting is timely, given that standard of care is shifting to incorporate immune checkpoint blockade in combination with EP in the first-line setting.

译文

在50例复发性SCLC患者中,联合OT显示出强烈的临床疗效信号。虽然交叉研究比较难以解释,但确认的ORR为41.7%,mPFS为4.2个月,数值上优于最近的一些二线和三线SCLC研究。在安慰剂对照的随机2期研究中加入veliparib至替莫唑胺也显示出改善的反应,进一步支持该策略。相比之下,使用PARP抑制剂塔拉唑巴的单药治疗在一期扩增研究中治疗的23名SCLC患者中仅导致2种部分反应,并且单药治疗olaparib在维持治疗后作为单一药物使用时与安慰剂相比没有赋予PFS益处。一线铂/依托泊苷。在我们的PDX模型中,组合优于单一疗法的优势也很明显,其中OT比单独的任一种药物显着更活跃(补充图2C)。总的来说,这些数据支持进一步发展将DNA损伤诱导与PARP抑制相结合的策略。 SCLC二线设置中的这种方法是及时的,因为标准护理正在转向将免疫检查点封锁与EP结合在一线设置中。